- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05942651
Impulsivity With Borderline Personality Disorder/tMS (IMPULSE)
Reduction of Impulsivity in Patients With Borderline Personality Disorder Using Dual-site Transcranial Magnetic Stimulation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Borderline personality disorder (BPD) is a mental disorder characterized by unstable interpersonal relationships, emotional lability and marked impulsivity. The latter manifests itself through risky behaviors such as substance abuse, self-harm and suicidal behavior.
Studies suggest that 1.3% of the general population suffers from BPD. However, in clinical settings, BPD patients represent 20% of all inpatients in psychiatric wards and up to 50% of patients hospitalized in emergency departments following a suicide attempt (SA). Moreover, it is estimated that nearly 84% of BPD patients will make at least one SA in their lifetime and up to 10% of them will die by suicide, a rate 50 times higher than the general population. Impulsivity, reflected in difficulties holding back action or stopping an action that has already begun, is one of the key symptoms of BPD.
Recent advances in non-invasive brain stimulation have led to the emergence of a new stimulation protocol known as Paired Cortico-Cortical Associative Stimulation (ccPAS), which consists of repeating paired stimulations using two TMS coils placed respectively on two cortical regions of interest. Paired stimulations' repetition induces plasticity by strengthening synaptic connectivity between the two targeted regions.
The aim of this project is to test the efficacy of a ccPAS protocol in enhancing effective connectivity between the IFC and pre-SMA in order to reduce impulsivity in BPD patients.
The Sponsor hypothesized that one ccPAS session, using two coils simultaneously, targeting the IFC and pre-SMA with a 'physiological' inter-stimulus interval of 4ms will improve motor inhibition abilities (reduce SSRT), compared to the group receiving 'control' ccPAS (100ms inter-stimulus interval (ccPAS100-ms)).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: POULET Emmanuel, PUPH
- Phone Number: +33 0437915565
- Email: emmanuel.poulet@chu-lyon.fr
Study Contact Backup
- Name: sartelet lydie
- Email: lydie.sartelet@ch-le-vinatier.fr
Study Locations
-
-
Aura
-
Bron, Aura, France, 69678 CEDEX
- Recruiting
- Centre Hospitalier Le Vinatier
-
Contact:
- POULET EMMANUEL, PUPH
- Phone Number: 0033437915120
- Email: emmanuel.poulet@chu-lyon.fr
-
Contact:
- VIAL VERONIQUE
- Phone Number: 0033437915531
- Email: veronique.vial@ch-le-vinatier.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of BPD (established by a psychiatrist and confirmed in a structured interview using the MINI) based on the Diagnostic and Statistical Manual of Mental Disorders (DSM V).
Exclusion Criteria:
- Contraindications to TMS/MRI (pacemakers or other devices likely to interfere with the magnetic field).
- Pregnant or breast-feeding women.
- Ongoing anxiolytic treatment (benzodiazepines), neuroleptic treatment or anticonvulsants acting on GABAergic transmission ; 24 hours prior to the protocol.
- Diagnosis of other chronic psychiatric pathology including bipolar disorder type I or II and addictions (except tobacco).
- Protective measure (curatorship or guardianship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: active ccPAS4-ms
Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I). Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline. The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT |
The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms.
A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
|
Sham Comparator: Control condition ccPAS100-ms.
Device: Magstim BiStim 2002 (The Magstim Company Ltd., Spring Gardens, Whitland, UK) and two small coils (40mm, figure-of-eight coils, Alpha B.I). Coil 1 was positioned over right IFC at a 20° angle to the coronal plane with the handle pointing anteriorly, and coil 2 was positioned over right pre- SMA perpendicular to the midline. The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT |
The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms.
A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Significant reduction in reaction time of the Emotional Stop Signal (SSRT) for the ccPAS4-ms group compared to the ccPAS100-ms sham group
Time Frame: 2 times: Outcome measure will be assessed: immediately before the ccPAS protocol and immediately after the ccPAS protocol, for both groups
|
The ability to inhibit an action (motor inhibition) is quantified using a 'Stop Signal' task in which the reaction time required to inhibit the action (SSRT) is calculated.
The longer the SSRT, the poorer the ability to inhibit an action and the greater the motor impulsivity
|
2 times: Outcome measure will be assessed: immediately before the ccPAS protocol and immediately after the ccPAS protocol, for both groups
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Increased effective inhibitory connectivity within the fronto-striatal network (DLPFC-M1), intracortical inhibition (short and long interval) and cortical silent period for the ccPAS4-ms group, when compared with the ccPAS100-ms group
Time Frame: 2 times: Outcome measure will be assessed: immediately before the ccPAS protocol and immediately after the ccPAS protocol, for both groups
|
Dual-site transcranial magnetic stimulation (TMS) can be used to probe effective connectivity between the left DLPFC and the left M1 (Wang et al. 2021).
Conditioned motor evoked potential (MEP) amplitude evoked by dual-site TMS and measured with surface electromyography (EMG) is compared to MEP amplitude evoked by TMS applied over M1 alone.
|
2 times: Outcome measure will be assessed: immediately before the ccPAS protocol and immediately after the ccPAS protocol, for both groups
|
Levels of intracortical inhibition within M1.
Time Frame: 1 time: Measured before the ccPAS protocol, in both groups.
|
Paired-pulse TMS provides a non-invasive method to study intracortical inhibitory circuits.
Short-interval intracortical inhibition (SICI) is a well-established paired-pulse measure of inhibitory circuitry within the M1 area.
SICI results from a subthreshold conditioning stimulus (CS) followed 3.5 ms later by a suprathreshold test stimulus (TS) delivered through the same coil over M1.
This measurement will be correlated with the other inhibition measurements (SSRT at baseline and duration of the silent period) to provide an overall view of the efficacy/inefficacy of this inhibitory system in patients with borderline personality disorder.
|
1 time: Measured before the ccPAS protocol, in both groups.
|
Duration of cortical silence period (in ms).
Time Frame: 1 time: Measured before the ccPAS protocol, in both groups
|
Single-pulse TMS applied over M1 during a voluntary contraction elicited a motor evoked potential followed immediately by a period of EMG silence that has been assumed to reflect intracortical inhibition.
This measurement will be correlated with the other inhibition measurements (SSRT at baseline and SICI) to provide an overall view of the efficacy/inefficacy of this inhibitory system in patients with borderline personality disorder.
|
1 time: Measured before the ccPAS protocol, in both groups
|
Cognitive task manipulating environment-emotion-behavior interactions.
Time Frame: 1 time: Measured before the ccPAS protocol, in both groups.
|
The task is framed to participants as being a fish gathering algae while predators might approach for which they need to check and if appropriate hide.
The task features differentially evoke emotions of stress and excitement.
Self-reported stress and threat-avoidance behaviors during the task will be measured.
|
1 time: Measured before the ccPAS protocol, in both groups.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-A00772-43
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Borderline Personality Disorder
-
University Hospital, Basel, SwitzerlandLeading House for the Latin American Region (Seed Money Grant SMG 1730)WithdrawnBorderline Personality Disorder (BPD)
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
University of EdinburghRecruitingEmotionally Unstable Personality Disorder, Borderline TypeUnited Kingdom
-
Silvia Elisa Hurtado SantiagoCompletedPersonality Disorder, BorderlineSpain
-
Health Service Executive, IrelandCompletedPersonality Disorder, Borderline
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownBorderline Personality Disorder.Spain
-
Universitat Jaume IHospital de la RiberaNot yet recruitingBorderline Personality Disorder (BPD)Spain
-
University of OldenburgProf. René Hurlemann; Jella Voelter, M.Sc.RecruitingBorderline Personality Disorder (BPD)Germany
-
NHS Greater Glasgow and ClydeUnknownBorderline Personality Disorder (BPD) | Antisocial Personality Disorder (ASPD)United Kingdom
-
Rutgers, The State University of New JerseyActive, not recruitingBorderline Personality Disorder in AdolescenceUnited States
Clinical Trials on Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.
-
Hôpital le VinatierFondation de FranceNot yet recruitingTreatment-resistant Depression